<DOC>
	<DOCNO>NCT01540461</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( PK ) , safety , tolerability Brivanib Chinese subject Advanced Hepatocellular Carcinoma ( HCC ) .</brief_summary>
	<brief_title>Determine Pharmacokinetics Safety Brivanib Chinese Subjects With Advanced Primary Liver Cancer ( Hepatocellular Carcinoma : HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Subjects : Confirmed Advanced Primary Liver Cancer ( Hepatocellular Carcinoma : HCC ) Not receive prior systemic treatment advance HCC Normal moderately impair liver function ( ChildPugh Class A B ( CP total score â‰¤ 7 ) ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Subjects : Brain metastasis evidence leptomeningeal disease History impair brain function ( encephalopathy ) active heart disease Unmanageable fluid abdomen ( ascites ) Bleeding esophageal gastric varix within 2 month prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HCC</keyword>
</DOC>